Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies.

Spinelli F, Capparelli E, Abate C, Colabufo NA, Contino M.

J Med Chem. 2017 Dec 28;60(24):9913-9931. doi: 10.1021/acs.jmedchem.7b00155. Epub 2017 Jun 30. Review.

PMID:
28608697
2.

New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.

Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G.

Eur J Med Chem. 2017 Feb 15;127:398-412. doi: 10.1016/j.ejmech.2017.01.002. Epub 2017 Jan 4.

PMID:
28088085
3.

Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease.

Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2219-2227. Epub 2016 Aug 3.

PMID:
27488857
4.

Functional CB2 type cannabinoid receptors at CNS synapses.

Morgan NH, Stanford IM, Woodhall GL.

Neuropharmacology. 2009 Sep;57(4):356-68. doi: 10.1016/j.neuropharm.2009.07.017. Epub 2009 Jul 16.

PMID:
19616018
5.

Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.

Mugnaini C, Brizzi A, Ligresti A, Allarà M, Lamponi S, Vacondio F, Silva C, Mor M, Di Marzo V, Corelli F.

J Med Chem. 2016 Feb 11;59(3):1052-67. doi: 10.1021/acs.jmedchem.5b01559. Epub 2016 Jan 26.

PMID:
26756097
6.

From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging.

Caillé F, Cacheux F, Peyronneau MA, Jego B, Jaumain E, Pottier G, Ullmer C, Grether U, Winkeler A, Dollé F, Damont A, Kuhnast B.

Mol Pharm. 2017 Nov 6;14(11):4064-4078. doi: 10.1021/acs.molpharmaceut.7b00746. Epub 2017 Oct 18.

PMID:
28968497
7.
8.

Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders.

Volcho KP, Laev SS, Ashraf GM, Aliev G, Salakhutdinov NF.

Curr Med Chem. 2018;25(39):5327-5346. doi: 10.2174/0929867324666170112101837. Review.

PMID:
28079000
9.

Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions.

Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y.

J Neurosci. 2012 Mar 21;32(12):4004-16. doi: 10.1523/JNEUROSCI.4628-11.2012.

10.

Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.

Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T.

Eur J Pharm Sci. 2015 Jan 25;67:85-96. doi: 10.1016/j.ejps.2014.11.003. Epub 2014 Nov 14.

PMID:
25447744
11.

Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay.

Martínez-Pinilla E, Rabal O, Reyes-Resina I, Zamarbide M, Navarro G, Sánchez-Arias JA, de Miguel I, Lanciego JL, Oyarzabal J, Franco R.

J Pharmacol Exp Ther. 2016 Sep;358(3):580-7. doi: 10.1124/jpet.116.234948. Epub 2016 Jun 29.

PMID:
27358483
12.

Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy.

Szczesniak AM, Porter RF, Toguri JT, Borowska-Fielding J, Gebremeskel S, Siwakoti A, Johnston B, Lehmann C, Kelly ME.

Neuropharmacology. 2017 Feb;113(Pt B):627-638. doi: 10.1016/j.neuropharm.2016.08.030. Epub 2016 Aug 25.

PMID:
27569993
13.

Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity.

Sun L, Dong R, Xu X, Yang X, Peng M.

J Neuroinflammation. 2017 Jul 19;14(1):138. doi: 10.1186/s12974-017-0913-7.

14.

Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.

Mugnaini C, Rabbito A, Brizzi A, Palombi N, Petrosino S, Verde R, Di Marzo V, Ligresti A, Corelli F.

Eur J Med Chem. 2019 Jan 1;161:239-251. doi: 10.1016/j.ejmech.2018.09.070. Epub 2018 Oct 13.

PMID:
30359820
15.

A Novel Selective Inverse Agonist of the CB2 Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies.

Martella A, Sijben H, Rufer AC, Grether U, Fingerle J, Ullmer C, Hartung T, IJzerman AP, van der Stelt M, Heitman LH.

Mol Pharmacol. 2017 Oct;92(4):389-400. doi: 10.1124/mol.117.108605. Epub 2017 Jul 26.

PMID:
28747489
16.

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Han S, Zhang FF, Qian HY, Chen LL, Pu JB, Xie X, Chen JZ.

Eur J Med Chem. 2015 Mar 26;93:16-32. doi: 10.1016/j.ejmech.2015.01.054. Epub 2015 Jan 26.

PMID:
25644673
17.

Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.

Turkman N, Shavrin A, Ivanov RA, Rabinovich B, Volgin A, Gelovani JG, Alauddin MM.

Bioorg Med Chem. 2011 Sep 15;19(18):5698-707. doi: 10.1016/j.bmc.2011.07.062. Epub 2011 Aug 5.

18.

Molecular imaging of human tumor cells that naturally overexpress type 2 cannabinoid receptors using a quinolone-based near-infrared fluorescent probe.

Wu Z, Shao P, Zhang S, Ling X, Bai M.

J Biomed Opt. 2014;19(7):76016. doi: 10.1117/1.JBO.19.7.076016.

PMID:
25036213
19.

Type-2 cannabinoid receptors in neurodegeneration.

Bisogno T, Oddi S, Piccoli A, Fazio D, Maccarrone M.

Pharmacol Res. 2016 Sep;111:721-730. doi: 10.1016/j.phrs.2016.07.021. Epub 2016 Jul 20. Review.

PMID:
27450295
20.

Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2 R Ligands To Combat Neurodegenerative Disorders.

Dolles D, Nimczick M, Scheiner M, Ramler J, Stadtmüller P, Sawatzky E, Drakopoulos A, Sotriffer C, Wittmann HJ, Strasser A, Decker M.

ChemMedChem. 2016 Jun 20;11(12):1270-83. doi: 10.1002/cmdc.201500418. Epub 2015 Nov 9.

PMID:
26548365

Supplemental Content

Support Center